ImmunoACT
Mumbai, India· Est.
India’s first indigenous CAR‑T developer delivering low‑cost, GMP‑grade therapies for B‑cell cancers.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
India’s first indigenous CAR‑T developer delivering low‑cost, GMP‑grade therapies for B‑cell cancers.
OncologyHematology
Technology Platform
Proprietary lentiviral vector platform coupled with in‑house plasmid manufacturing enables high‑titer, GMP‑compliant production of autologous CAR‑T cells.
Opportunities
Scaling manufacturing capacity to 1,500 patients/year and expanding into African markets while developing next‑generation CAR‑T candidates.
Risk Factors
Regulatory complexity, high manufacturing costs, and intense competition from established global CAR‑T developers.
Competitive Landscape
Competes with Novartis, Gilead, and emerging Indian cell‑therapy firms; differentiation lies in an indigenous platform and low‑cost pricing model.